A Study to Evaluate the Efficacy and Safety of Rosuvastatin in the Treatment of the Carotid Atherosclerotic Plaques

Inclusion Criteria: * Subjects or legal guardian can understand and sign the written informed consent form; * LDL-C≥100mg/dl（2.6mmol/l）. * Subjects with carotid atherosclerotic non-calcified plaques determined by color Doppler ultrasound on carotid. ( Plaque defined as limited intima media thickness≥1.5mm, according to the procedure of vascular ultrasound examination in 2009 Chinese Journal of Ultrasonography ) * Subjects had not been treated with statins, or one had been treated with antihyperlipidemics no more than 3 months within 12 months prior to screening. Exclusion Criteria: * Subjects known to be allergic to the study medication, or any components . * Uncontrolled hypothyroidism defined as the systolic blood pressure(SBP) \>180 mmHg or the diastolic blood pressure(DBP) \>100 mmHg. * Concomitant with severe or frequent arrhythmia, such as Atrial Fibrillation, second or third degree Atrioventricular Block, Sick sinus Syndrome etc. * Alanine aminotransaminase (ALT) and /or Aspartate aminotransferase (AST) \>1.5×ULN (upper limit of normal). * Subjects with myopathies，or the value of Creatine kinase \>1.5×ULN (upper limit of normal). * Concomitant with chronic wasting diseases, whose life span was anticipated no longer than 2 years. * Pregnant or nursing woman, and subjects with a Pregnant plan during this study. * Cognitive impairment, which may affect obtaining informed consent and participating in the study procedures. * Unwilling to receive treatment or examinations outlined in protocol.